Gilead halted after report Remdesivir flopped in coronavirus trial

CNBC's "Halftime Report" team discusses a report that says Gilead medicine flopped in a trial. The Financial Times said—citing documents accidentally published by the World Organization—that Remdesivir did not improve patients' condition or reduce the coronavirus pathogen in their bloodstream. Equities had initially rallied as crude prices continued their rebound from historic lows.